Pfizer, Inc. · NYSE:PFE

Pfizer — 2009 Deutsche Bank 34th Annual Health Care Conference

12 slides from Pfizer's conference presentation, May 19, 2009

  1. Slide 1: 2009 Deutsche Bank 34th Annual Health Care Conference

    2009 Deutsche Bank 34th Annual Health Care Conference May 19, 2009 Frank D’Amelio Senior Vice President & Chief Financial Officer

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information ' ƒ Our discussions during this presentation will include forward- looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ ar

  3. Slide 3: Top Investor Discussion Topics

    Top Investor Discussion Topics ' ƒ 2009 Financial Guidance ƒ BU/R&D Structure ƒ Integration Process and Progress ƒ Regulatory Pathway for Approval ƒ 2012 Financial Targets ƒ Financial Priorities and Considerations Given Strong Cash Flow Target in 2012 ƒ Potential Legislative Reform Initiatives 3

  4. Slide 4: 2009 Financial Guidance

    2009 Financial Guidance ' Guidance(3), (5) Reported Revenues $44.0 to $46.0 Billion Adjusted Cost of Sales(2) 14.5% to 15.5% as a Percentage of Revenues Adjusted SI&A Expenses(2) $13.5 to $14.0 Billion Adjusted R&D Expenses(2) $7.1 to $7.5 Billion Adjusted Other Income(2) $500 to $700 Million $1.20

  5. Slide 5: Planned Business Structure To Provide Flexibility & Accountability

    Planned Business Structure To Provide Flexibility & Accountability ' BioPharmaceuticals Specialty Primary Established Emerging Care & Oncology Care Products Markets Vaccines Diversified Consumer Nutritional Animal Health Capsugel Health Health PharmaTherapeutics Business Units and BioTherapeutics Re

  6. Slide 6: Commercial Operations Structure Following Wyeth Closing

    Commercial Operations Structure Following Wyeth Closing ' BioPharmaceuticals Diversified Businesses Ian Read, Group President Cavan Redmond, Group President Specialty Primary Emerging Established Animal Consumer Care and Oncology Capsugel Nutritional Care Markets Products Health Health Vaccines Heal

  7. Slide 7: Biopharmaceutical Research Following Wyeth Closing

    Biopharmaceutical Research Following Wyeth Closing ' PharmaTherapeutics BioTherapeutics Research Group Research Group (Small Molecule) (Large Molecule/Vaccines) Dr. Martin Mackay, President Dr. Mikael Dolsten, President ƒ Two Research Groups delivering positive Proofs of Concept for the Business Uni

  8. Slide 8: Pending Wyeth Acquisition Planning Update

    Pending Wyeth Acquisition Planning Update ' Progress to Date Work to be Completed ƒ Syndicated bridge loan to 34 banks ƒ Continue to execute on 2009 goals ƒ Finalized credit agreements ƒ Obtain regulatory approvals – FTC, EU, China, etc. ƒ Filed HSR notification – Received expected Second Request ƒ

  9. Slide 9: 2012 Financial Targets

    2012 Financial Targets ' Total Revenues Comparable to pro forma 2008 results of ~$70 billion Adjusted Operating Margin(1) High 30%s to Low 40%s Adjusted Diluted EPS(1) Comparable to Pfizer 2008 results of $2.42 Operating Cash Flow $20+ billion Cash Position Net positive No product projected to repre

  10. Slide 10: Financial Priorities

    Financial Priorities ' $20+B in Operating Cash Flow with Net Cash Position Targeted in 2012 Repay Debt Reinvest to Support EPS Growth Maintain Flexibility Repatriate Less Dividend Payment Offshore Cash Share Repurchase 10

  11. Slide 11: Potential Legislative Reform Initiatives

    Potential Legislative Reform Initiatives ' ƒ Expansion of Coverage ƒ Medicaid Rebate Changes ƒ Incentive to Innovate ƒ Focus on Preventative Care ƒ Tax Reform for Multinational Corporations 11

  12. Slide 12: 2009 Deutsche Bank 34th Annual Health Care Conference

    2009 Deutsche Bank 34th Annual Health Care Conference May 19, 2009 Frank D’Amelio Senior Vice President & Chief Financial Officer

Pfizer — 2009 Deutsche Bank 34th Annual Health Care Conference on 6ix